UniSuper Management Pty Ltd Decreases Holdings in Eli Lilly and Company (NYSE:LLY)

UniSuper Management Pty Ltd decreased its holdings in Eli Lilly and Company (NYSE:LLY) by 3.6% in the fourth quarter, Holdings Channel reports. The fund owned 144,682 shares of the company’s stock after selling 5,364 shares during the quarter. Eli Lilly and Company makes up 0.8% of UniSuper Management Pty Ltd’s holdings, making the stock its 20th biggest holding. UniSuper Management Pty Ltd’s holdings in Eli Lilly and Company were worth $111,695,000 at the end of the most recent reporting period.

Several other large investors also recently added to or reduced their stakes in the stock. Principal Financial Group Inc. lifted its position in Eli Lilly and Company by 5.3% in the third quarter. Principal Financial Group Inc. now owns 1,208,545 shares of the company’s stock worth $1,070,698,000 after buying an additional 60,306 shares during the last quarter. Penserra Capital Management LLC raised its stake in shares of Eli Lilly and Company by 45.2% in the third quarter. Penserra Capital Management LLC now owns 870 shares of the company’s stock valued at $770,000 after acquiring an additional 271 shares during the period. Loomis Sayles & Co. L P lifted its holdings in shares of Eli Lilly and Company by 24.7% in the 3rd quarter. Loomis Sayles & Co. L P now owns 1,869 shares of the company’s stock worth $1,656,000 after acquiring an additional 370 shares during the last quarter. Quantbot Technologies LP boosted its stake in shares of Eli Lilly and Company by 115.3% during the 3rd quarter. Quantbot Technologies LP now owns 3,757 shares of the company’s stock worth $3,328,000 after purchasing an additional 2,012 shares during the period. Finally, Baldwin Investment Management LLC grew its holdings in Eli Lilly and Company by 2.4% during the 3rd quarter. Baldwin Investment Management LLC now owns 8,354 shares of the company’s stock valued at $7,401,000 after purchasing an additional 195 shares during the last quarter. 82.53% of the stock is owned by institutional investors.

Insider Activity

In related news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction that occurred on Thursday, March 13th. The shares were sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the sale, the chief accounting officer now owns 5,840 shares of the company’s stock, valued at $4,778,521.60. This represents a 14.62 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of NYSE:LLY opened at $826.84 on Thursday. Eli Lilly and Company has a 52 week low of $711.40 and a 52 week high of $972.53. The firm has a 50 day moving average of $841.16 and a 200 day moving average of $837.54. The company has a market capitalization of $783.98 billion, a price-to-earnings ratio of 70.61, a price-to-earnings-growth ratio of 1.40 and a beta of 0.34. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing analysts’ consensus estimates of $5.45 by ($0.13). Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. On average, sell-side analysts predict that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company declared that its Board of Directors has initiated a share repurchase program on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to repurchase up to 2% of its shares through open market purchases. Shares buyback programs are typically an indication that the company’s management believes its stock is undervalued.

Analysts Set New Price Targets

Several analysts have issued reports on the stock. Wells Fargo & Company raised their price objective on shares of Eli Lilly and Company from $970.00 to $1,100.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Leerink Partners set a $950.00 price objective on Eli Lilly and Company in a report on Friday, January 17th. Citigroup reduced their target price on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Berenberg Bank set a $970.00 target price on shares of Eli Lilly and Company in a research note on Thursday, January 16th. Finally, Truist Financial upped their price target on shares of Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a “buy” rating in a report on Monday, February 3rd. Three analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,009.72.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.